Abstract
Introduction of a 1-benzyl-1H-pyrazol-4-yl moiety at C7 of the imidazo[4,5-b]pyridine scaffold provided 7a which inhibited a range of kinases including Aurora-A. Modification of the benzyl group in 7a, and subsequent co-crystallisation of the resulting analogues with Aurora-A indicated distinct differences in binding mode dependent upon the pyrazole N-substituent. Compounds 7a and 14d interact with the P-loop whereas 14a and 14b engage with Thr217 in the post-hinge region. These crystallographic insights provide options for the design of compounds interacting with the DFG motif or with Thr217.
Keywords:
Aurora kinase; Aurora-A; Imidazo[4,5-b]pyridine.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Aurora Kinases / antagonists & inhibitors*
-
Aurora Kinases / chemistry*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Crystallization
-
Dose-Response Relationship, Drug
-
Humans
-
Imidazoles / chemical synthesis*
-
Imidazoles / chemistry
-
Imidazoles / pharmacology*
-
Mice
-
Microsomes, Liver / chemistry
-
Microsomes, Liver / metabolism
-
Models, Molecular
-
Molecular Structure
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrazoles / chemical synthesis*
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology*
-
Pyridines / chemical synthesis*
-
Pyridines / chemistry
-
Pyridines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Imidazoles
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Aurora Kinases